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SHORT REPORT

Open Access

Development and evaluation of a replicon
particle vaccine expressing the E2 glycoprotein of
bovine viral diarrhea virus (BVDV) in cattle
John Dustin Loy1,5*, Jill Gander1, Mark Mogler1,2, Ryan Vander Veen1, Julia Ridpath3, Delbert Hank Harris1,2,4
and Kurt Kamrud1,2

Abstract
Background: Bovine viral diarrhea virus is one of the most significant and costly viral pathogens of cattle
worldwide. Alphavirus-derived replicon particles have been shown to be safe and highly effective vaccine vectors
against a variety of human and veterinary pathogens. Replicon particles are non-propagating, DIVA compatible, and
can induce both humoral and cell mediated immune responses. This is the first experiment to demonstrate that
Alphavirus-based replicon particles can be utilized in a standard prime/boost vaccination strategy in calves against a
commercially significant bovine pathogen.
Findings: Replicon particles that express bovine viral diarrhea virus sub-genotype 1b E2 glycoprotein were
generated and expression was confirmed in vitro using polyclonal and monoclonal antibodies specific to E2.
Vaccine made from particles was generated in Vero cells and administered to BVDV free calves in a prime/boost
regimen at two dosage levels. Vaccination resulted in neutralizing antibody titers that cross-neutralized both type 1
and type 2 BVD genotypes following booster vaccination. Additionally, high dose vaccine administration
demonstrated some protection from clinical disease and significantly reduced the degree of leukopenia caused by
viral infection.
Conclusions: Replicon particle vaccines administered in a prime/boost regimen expressing BVDV E2 glycoprotein
can induce cross-neutralizing titers, reduce leukopenia post challenge, and mitigate clinical disease in calves. This
strategy holds promise for a safe and effective vaccine to BVDV.
Keywords: BVD, Bovine viral diarrhea virus, Alphavirus replicon, Replicon particle, Vaccine

Findings
Background

Bovine viral diarrhea virus (BVDV) is an enveloped,
positive strand RNA virus in the genus Pestivirus (family
Flaviviridae), and is the causative agent of bovine viral
diarrhea (BVD). BVD is one of the most economically
significant bovine diseases in the world. Production
losses, estimated on a population level, are thought to be
$10–40 million US per million calvings [1]. Classically,
BVDV has been associated with acute enteric disease;
however, BVDV is now understood to be responsible for
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a broad range of clinical illnesses in cattle including respiratory disease, reproductive loss, and fetal infections
[2]. The BVDV E2 gene encodes a 53 kDa major structural glycoprotein that contains a neutralizing epitope
that varies among strains [3]. Monoclonal antibodies
specific to E2 demonstrate virus neutralizing (VN) ability
against both cytopathic and noncytopathic strains of
BVDV [4]. Current strategies to reduce losses caused by
BVD in infected herds include vaccination with modified
live (MLV) or inactivated vaccines and elimination of
persistently infected animals. There are no commercially
available recombinant or vectored vaccines, and thus
producers are limited to either modified live MLV or inactivated vaccine approaches [5]. Additionally, some success
has been shown experimentally using BVD pseudovirions,
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which have a deletion in the structural genes, and are
rescued using homologous helper RNA in trans [6].
A replicon-based expression system has been derived
from the alphavirus (family Togaviridae) Venezuelan
Equine Encephalitis (VEE) virus [7,8]. Alphavirus-based
replicon particles have numerous advantages for vaccine
development including; accurate production of native
proteins and a propagation-defective nature that makes
the system only capable of a single infection cycle [9].
This viral vector has previously been used to express
genes from numerous pathogens including human
strains of influenza virus, simian immunodeficiency
virus, Norwalk virus, Ebola virus, smallpox virus, Lassa
virus, and equine arteritis virus [10-16]. RP have a robust
safety profile. It has been demonstrated that RP are not
shed from vaccinated animals and as such cannot spread
to unvaccinated animals. Furthermore, RP have been
tested for the presence of replication competent virus
that may arise by recombination during production of
RP and have been shown to lack the ability to revert to
virulence [17]. Alphavirus RP have also been tested in
cattle against foot and mouth disease virus (FMDV)
(Kurt Kamrud, personal communication) but have not
been tested against a commercially-significant cattle disease in the United States using a prime/boost vaccination
strategy. Therefore, it is proposed that alphavirus RP that
express the E2 glycoprotein from BVDV would provide a
novel, safe, and effective approach to control BVD.
Methods

The E2 glycoprotein gene was de novo synthesized
(DNA2.0) using sequence from BVDV subgenotype 1b
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strain NY1 (Genbank: AY027671). The E2 gene was
cloned into a replicon vector plasmid as previously
described [8] and the sequence was confirmed to ensure
no mutations were introduced in the cloning process.
RNA was generated by in vitro transcription of linearized
replicon plasmid DNA using T7 RNA polymerase as
described previously [8]. RP were generated by coelectroporation of E2 replicon RNA and structural gene
helper RNAs into Vero cells and subsequent harvest of
the particles [16]. Vero cell monolayers were then infected
with E2 RP at an MOI of 10 and the presence of E2
expression was confirmed by western blot analysis of E2
RP infected cell lysates using hyperimmune polyclonal
swine serum (data not shown). In addition, E2 protein expression was confirmed by indirect immunofluorescence
assay using E2 specific monoclonal antibodies (Figure 1).
Seven (7) calves, 8 weeks of age, were sourced from a
BVD free herd. Each animal was tested and found negative for BVDV antibodies by viral neutralization assay
(VN), BVDV antigen in earnotch samples (BVD immunohistochemistry), and were negative for circulating
virus in whole blood by PCR. Three (3) calves were
randomly assigned to each of 2 blocks (experimental
groups) and one (1) calf was assigned to a single block
(placebo). The calves were acclimated for 7 days before
onset of the trial. Calves were injected intramuscularly
(IM) with 2 mL of 5 × 106 infectious units (IU)/mL RP
(1 × 107 IU total), 5 × 105 IU/mL RP (1 × 106 IU total), or
a placebo control of RP diluent (1% normal bovine
serum, 5% sucrose in PBS). Personnel sampling and
scoring the animals were blinded to the treatment
groups.

Figure 1 Indirect immunofluorescence assay of replicon particle (RP) infected Vero cells. Vero cell monolayers were infected with RP
expressing either (A) the E2 glycoprotein gene of BVDV subgenotype 1b strain NY1 or (B) a non-BVDV-derived gene as a control. Cells were fixed
and subsequently stained with a monoclonal antibody specific to BVDV 1b E2 and a fluorescent-conjugated anti-mouse secondary antibody.
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Figure 2 Geometric mean of viral neutralizing antibody dilutions on day of virus challenge. The 1×107 IU vaccinated group had
significantly higher geometric mean VN titers (P=.04 by oneway ANOVA) than the 1×106 IU dosage level. Reference strains used were Singer
(type 1) and 296c (type 2).

Serum was collected from calves on days 0, 21, 28, 35,
42, 49, and on 56. Whole blood was collected in tubes
containing EDTA 1 day prior to challenge through 14
days post challenge (a total of 16 days). On day 42 animals were challenged with 1×106 TCID50/mL of BVD1b
strain NY1 intranasally (USDA distributed efficacy challenge material). Neutralizing antibody responses were
assessed using representative viruses from Type 1 and
Type II BVDV strains (Singer and 296c, respectively)

using day 0, 21, 28, and 42 serum samples. Clinical
disease was scored on a scale from 0–3 each day. White
blood cell (WBC) counts were assessed on whole blood
samples collected in tubes containing EDTA using an
automated cell counter (Iowa State University, Veterinary
Pathology). The degree of leukopenia following virus challenge was assessed by subtracting the maximum reduction
in circulating WBCs from the baseline level (calculated
from a mean of two samples prior to challenge).
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Figure 3 Y-axis is percent depletion of circulating white blood cells when compared to pre-challenge baseline (set to 100%). The
highest levels of depletion were seen in the placebo groups with a dose dependent decrease in WBC reduction in vaccinated groups. Error bars
indicate standard error from mean percentage depletion.

Loy et al. Virology Journal 2013, 10:35
http://www.virologyj.com/content/10/1/35

Page 4 of 5

106

105

1E7 IU

104

103

1E6 IU

102
Placebo
Vaccination

101

100
-1

0

1

2

3

4

5

6

7

8

9

10 11 12 13 14

Figure 4 Mean rectal temperatures (°F) post challenge with BVD1b NY1 (Y-axis.) X-axis is days post viral challenge. Error bars indicate
standard error from mean.

Results

Serum from the control animal was VN negative on the
day of challenge. A dose dependent heterologous VN response was observed in animals to sub-genotypes BVD1a
and BVD2. VN titers were induced in all vaccinated animals to Type 1 strains and most animals to Type 2 strains
in the high dose group. Significant differences by one-way
ANOVA were observed in VN geometric mean titers
between low and high dose E2 RP vaccinated groups
(Figure 2). The serum of all E2 RP vaccinated animals was
positive at termination by western immunoblotting against
recombinant E2 glycoprotein. Both E2 RP treated groups

showed a reduced degree of leukopenia when compared
with the control; the high dose E2 RP dose having a
greater impact on reducing leukopenia (Figure 3). Febrile
responses were noted in all animals at some study timepoint following virus challenge (Figure 4). The placebo
group demonstrated a febrile response before E2 RP vaccinated animals at 3 days post challenge (dpc) (Figure 4).
All experimental groups demonstrated febrile responses
from days 7–9 post challenge with a maximum of 105.8°F
(Figure 4). Temperatures returned to normal levels in all
E2 RP vaccinated animals by day 9 post challenge;
however, temperatures remained elevated for several
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Figure 5 Mean clinical scores over the course of the study. Scores were based on presence of mild nasal discharge, mild ocular discharge, or
mild depression. No differences were seen in clinical outcomes between low dose E2 RP and placebo controls in clinical disease.
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additional days in the control animal (Figure 4). Clinical
disease scores (nasal/ocular discharge and/or depression)
were collected for all animals. Protection from clinical disease after challenge was noted in 2 of the 3 high dose E2
RP vaccinated animals. The clinical disease scores for the
low dose E2 RP group and placebo control were not different (mean clinical score = 4); In contrast, the high dose E2
RP group demonstrated significantly reduced disease
severity and degree of clinical signs (mean clinical score =
0.66) (Figure 5).
In summary, these data demonstrate that RP expressing
BVD1b NY1 E2 glycoprotein can induce dose dependent
immune responses specific to BVDV. Importantly, the E2
RP induce a cross-reactive VN antibody response to Type
1a and Type 2 BVD strains. This response was significantly higher in animals that received the 1 × 107 IU E2
RP dosage level. Furthermore, the vaccine impacted
clinical parameters post-challenge with a homologous
BVDV strain and reduced the degree of leukopenia postchallenge when compared to the control. The current
study does not address if the heterologous neutralization
titers indicate efficacy against heterologous challenge,
however, this will be addressed in future experiments. We
believe that BVDV E2 RP represent an attractive alternative to MLV or inactivated vaccine approaches because of
the efficacy demonstrated here, the safety profile of the
vector, and because E2 RP may allow differentiation of
infected and vaccinated animals capable of supporting
BVDV eradication programs.
The use of biohazardous materials and the calf
experimental protocol were reviewed and approved by
the ISU Institutional Biosafety Committee (IBC) and
the Institutional Animal Care and Use Committee
(9-11-7225-B).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JDL, KIK, and DLH conceived the study. JDL, MAM, JRG, RVV and KIK
developed, manufactured, and tested the vaccine. JR performed assays and
provided guidance. JDL wrote the manuscript. All authors read and
approved the manuscript.
Acknowledgments
The authors would like to thank Kara Burrack, Kay Kimpston-Burkgren, Lyle
Kesl, and Kara Jimenez for their contributions.
Author details
1
Harrisvaccines, Inc, 1102 Southern Hills Dr. Suite 101, Ames, IA 50010, USA.
2
Department of Animal Science, Iowa State University, Kildee Hall, Ames, IA
50011, USA. 3United States Department of Agriculture, Agricultural Research
Service, Ruminant Diseases and Immunology Research Unit, Ames, IA 50010,
USA. 4Department of Veterinary Diagnostic and Preventive Medicine, Iowa
State University, Ames, IA 50011, USA. 5University of Nebraska-Lincoln,
Department of Veterinary and Biomedical Sciences, Lincoln, NE 68502-0907,
USA.
Received: 23 July 2012 Accepted: 22 January 2013
Published: 28 January 2013

Page 5 of 5

References
1. Houe H: Economic impact of BVDV infection in dairies. Biologicals 2003,
31(2):137–143.
2. Evermann JF, Barrington JM: Clinical features. In Bovine Viral Diarrhea Virus:
Diagnosis, Management,and Control. 1 edition. Edited by Goyal SM, Ridpath
JF. Ames: Wiley-Blackwell; 2005:105–120.
3. Hansen TR, Smirnova NP, Van Campen HF, Shoemaker ML, Ptitsyn AA,
Bielefeldt-Ohmann H: Maternal and fetal response to fetal persistent
infection with bovine viral diarrhea virus. Am J Reprod Immunol 2011,
64(4):293–306.
4. Donis RO, Corapi WF, Dubovi EJ: Neutralizing monoclonal antibodies to
bovine viral diarrhoea virus bind to the 56K to 58K glycoprotein.
J Gen Virol 1988, 69:77–86.
5. Rodning SP, Marley MS, Zhang YF, Eason AB, Nunley CL, Walz PH, Riddell KP,
Galik PK, Brodersen BW, Givens MD: Comparison of three commercial
vaccines for preventing persistent infection with bovine viral diarrhea
virus. Theriogenology 2010, 73(8):1154–1163.
6. Zemke J, König P, Mischkale K, Reimann I, Beer M: Novel BVDV-2 mutants
as new candidates for modified-live vaccines. Vet Microbiol 2010,
142:69–80.
7. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF: Repliconhelper systems from attenuated Venezuelan equine encephalitis virus:
expression of heterologous genes in vitro and immunization against
heterologous pathogens in vivo. Virology 1997, 239:389–401.
8. Kamrud KI, Custer M, Dudek JM, Owens G, Alterson KD, Lee JS, Groebner JL,
Smith JF: Alphavirus replicon approach to promoterless analysis of IRES
elements. Virology 2007, 360:376–387.
9. Vander Veen RL, Harris DL, Kamrud KI: Alphavirus replicon vaccines.
Anim Health Res Rev 2012, 13:1–9.
10. Balasuriya UBR, Heidner HW, Davis NL, Wagner HM, Hullinger PJ, Hedges JF,
Williams JC, Johnston RE, Wilson WD, Liu IK, et al: Alphavirus replicon
particles expressing the two major envelope proteins of equine arteritis
virus induce high level protection against challenge with virulent virus
in vaccinated horses. Vaccine 2002, 20:1609–1617.
11. Balasuriya UBR, Heidner HW, Hedges JF, Williams JQ, Davis NL, Johnston RE,
Maclachlan NJ: Expression of the Two major envelope proteins of equine
arteritis virus as a heterodimer is necessary for induction of neutralizing
antibodies in mice immunized with recombinant Venezuelan equine
encephalitis virus replicon particles. J Virol 2000, 74:10623–10630.
12. Davis NL, Caley IJ, Brown KW, Betts MR, Irlbeck DM, McGrath KM, Connell
MJ, Montefiori DC, Frelinger JA, Swanstrom R, et al: Vaccination of
macaques against pathogenic Simian immunodeficiency virus with
Venezuelan equine encephalitis virus replicon particles. J Virol 2000,
74:371–378.
13. Harrington PR, Yount B, Johnston RE, Davis N, Moe C, Baric RS: Systemic,
mucosal, and heterotypic immune induction in mice inoculated with
Venezuelan equine encephalitis replicons expressing Norwalk virus-like
particles. J Virol 2002, 76:730–742.
14. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J: Individual and bivalent
vaccines based on alphavirus replicons protect guinea pigs against
infection with Lassa and Ebola viruses. J Virol 2001, 75:11677–11685.
15. Schultz-Cherry S, Dybing JK, Davis NL, Williamson C, Suarez DL, Johnston R,
Perdue ML: Influenza virus (a/HK/156/97) hemagglutinin expressed by an
alphavirus replicon system protects chickens against lethal infection
with Hong Kong-origin H5N1 viruses. Virology 2000, 278:55–59.
16. Hooper JW, Ferro AM, Golden JW, Sivera P, Dudek JM, Alterson KD,
Custer M, Rivers B, Morris J, Owens G, et al: Molecular smallpox vaccine
delivered by alphavirus replicons elicits protective immunity in mice and
Non-human primates. Vaccine 2009, 28(2):494–511.
17. Vander Veen RL, Loynachan AT, Mogler MA, Russell BJ, Harris DL, Kamrud KI:
Safety, immunogenicity, and efficacy of an alphavirus replicon-based
swine influenza virus hemagglutinin vaccine. Vaccine 2012, 30:1944–1950.
doi:10.1186/1743-422X-10-35
Cite this article as: Loy et al.: Development and evaluation of a replicon
particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea
virus (BVDV) in cattle. Virology Journal 2013 10:35.

